GlassScriptPhysician profile
Rajesh M Mehta
NPI 1588677355
$1,951.58
in general payments reported to CMS, 2019-2025
26 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $136 · 2021: $205 · 2022: $223 · 2023: $288 · 2024: $343 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.37 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $242.66 | 2019-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.68 | 2019-2025 | Relistor |
| Boston Scientific Corporation | $150.49 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept |
| Biodelivery Sciences International, INC. | $90.68 | 2019-2021 | |
| Allergan, INC. | $89.64 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $80.07 | 2019-2020 | |
| Lundbeck LLC | $76.30 | 2021-2025 | Vyepti |
| Si-Bone, INC. | $73.50 | 2019-2023 | |
| Lilly USA, LLC | $66.53 | 2019-2021 | |
| Virtus Pharmaceuticals LLC | $61.96 | 2024 | Levorphanol Tartrate |
| Amgen INC. | $58.14 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $56.00 | 2024-2025 | |
| Averitas Pharma INC. | $55.17 | 2025 | Qutenza |
| Medtronic, INC. | $50.96 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $44.34 | 2022 | |
| Almatica Pharma LLC | $33.25 | 2023 | Gralise |
| Mdd US Operations, LLC | $25.65 | 2019 | |
| Daiichi Sankyo INC. | $23.13 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.69 | 2023 | Keveyis |
| Irhythm Technologies, INC. | $21.32 | 2020 | |
| Tonix Medicines, INC. | $16.99 | 2025 | Tonmya |
| Grt US Holding, INC. | $16.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.12 | 2020 | |
| Protega Pharmaceutials INC | $13.01 | 2023 | Roxybond |
| Pfizer INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.